Cholinergic differentiation factors (CDFs) suppress noradrenergic properties and induce cholinergic properties in sympathetic neurons. The CDFs leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) bind to a LIFR/gp130 receptor complex to activate Jak/signal transducers and activators of transcription and Ras/ mitogen activated protein kinases (MAPK) signaling pathways. Little is known about how these differentiation factors suppress noradrenergic properties. We used sympathetic neurons and SK-N-BE(2)M17 neuroblastoma cells to investigate CDF downregulation of the norepinephrine synthetic enzyme dopamine-β-hydroxylase (DBH). LIF and CNTF activated ERK 1&2 (Extracellular Signal-Regulated Kinases) but not p38 or Jun N-terminal kinases in both cell types. Preventing ERK activation with PD98059 blocked CNTF suppression of DBH protein in sympathetic neurons, but did not prevent the loss of DBH mRNA. CNTF decreased transcription of a DBH promoter-luciferase reporter construct in SK-N-BE(2)M17 cells, and this was also ERK-independent.
Introduction
Cholinergic differentiation factors (CDFs) 1 suppress noradrenergic properties, and induce cholinergic and peptidergic properties in sympathetic neurons. This occurs during development in response to target-derived differentiation factors (1) , and occurs following nerve injury due to the release of inflammatory cytokines (2) . The developmental and injury-induced cholinergic differentiation factors that have been characterized to date are related to the inflammatory cytokine interleukin-6 (IL-6).
The interleukin-6 cytokine family includes leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1, oncostatin M and a sweat gland-derived differentiation factor. All interleukin-6 family members share the common signaling receptor gp130. Interleukin-6 uses a gp130 homodimer, while all other family members activate a gp130/LIFR heterodimer (3) (4) (5) (6) (7) (8) . Several IL-6 family members require an additional receptor subunit for cytokine binding, but signal transduction occurs through the gp130/LIFR complexes.
Binding of these cytokines to their receptors induces dimerization of receptor subunits and activation of Janus tyrosine kinases (Jak1/Jak2 and Tyk2), which are constitutively associated with the receptors (9) (10) (11) . Ligand binding activates at least two major signaling cascades: a Jak/STAT (Signal Transducers and Activators of Transcription) pathway (12) (13) (14) (15) (16) , and a Ras/MAPK (Mitogen Activated Protein Kinase) pathway (17) . Upon phosphorylation by Jaks, STATs dimerize and translocate to the nucleus where they bind to cytokine responsive elements to induce gene transcription. Mitogen activated protein kinases are serine/threonine kinases that exist in modules containing a three-kinase cascade. There are a least three classes of MAP kinases activated in separate modules: ERKs (Extracellular Signal-Regulated Kinases), JNK/SAPKs (c-Jun Nterminal Kinases/Stress-Activated Protein Kinases) and p38s (18) . Each of these types of kinases can be activated by IL-6 related cytokines in different cell types. The induction of cholinergic and peptidergic properties in sympathetic neurons requires STAT activation, and can be modified by stimulation of the Ras/MAPK pathway (19) .
In contrast to our knowledge of the signaling mechanisms that induce peptidergic properties, little is known about the mechanisms that suppress noradrenergic function. To identify the signaling pathways important for the loss of norepinephrine, we investigated the regulation of dopamine-β-hydroxylase (DBH), the enzyme that converts dopamine to NE. DBH is suppressed by cholinergic differentiation factors both in vivo (20) and in vitro (21) . Inasmuch as STATs typically induce transcription, we hypothesized that the suppression of DBH occurred primarily through a Ras/MAPK pathway.
We investigated the role of MAP kinases in cytokine-induced downregulation of DBH mRNA and protein in sympathetic neurons. In addition, we examined cytokine regulation of DBH promoter activity in SK-N-BE(2)M17 neuroblastoma cells. In both cell types we found that ERK 1&2 were activated by LIF and CNTF, while p38 and JNKs were not. Surprisingly, preventing ERK activation blocked suppression of DBH protein, but not the decrease in DBH mRNA or promoter activity. The chronic absence of ERK activity elevated basal DBH transcription and mRNA, suggesting that ERK inhibits basal DBH transcription but does not mediate the cytokine suppression of DBH mRNA. Cell lines and Cell culture: Primary cultures of superior cervical ganglia were prepared as described previously (22;23) . Cells were preplated for 1-2 hours to deplete nonneuronal cells, and were plated onto 96 well BioCoat plates or poly-L-lysine/laminin coated plates at a density of 1000-2000 cells per well. Neurons were cultured in L-15 complete supplemented with 50 ng/ml 2.5s NGF, 5% FBS, 100 U/mL penicillin G, and 100 µg/mL streptomycin sulfate. Prior to any treatments, neurons were maintained for two days in the antimitotic agents fluorodeoxyuridine and uridine (10 ¼M each) to further deplete non-neuronal cells.
SK-N-BE(2)M17 cells were grown in DMEM supplemented with 10% FBS and maintained in 5% CO 2 . For acute phosphorylation experiments, M17 cells were plated at 5x10 5 cells per well in 6 well plates. For chronic (5 day) cytokine treatments, M17 cells were plated at 2-2.5 x 10 5 cells per well in 6 well plates. MAP Kinase phosphorylation: A time course identified 15 minutes as the peak activity for LIF-activated phospho-ERK 1/2. Therefore, cytokines were added at the indicated concentration for 15 min. Sympathetic neurons were treated with PD98059 or U0126 (24) for 30 min prior to addition of cytokine. Cells were placed on ice and collected in ERK lysis buffer (1% IGEPAL, 20 mM Tris HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM EDTA, 10 mM NaF with 1 mM PMSF, 1 µg /ml Leupeptin, and 1 mM Vanadate). 6x loading buffer (12% SDS, 60 % glycerol, 360 mM Tris, pH 6.8, and 0.06% bromophenol blue with 600 mM DTT) was added to a total volume of 70 µl before samples were heated at 95ºC for 5 min and separated on a 10% acrylamide gel. M17 cells were treated as above with cytokine and lysed directly in SDS Sample Buffer (62.5 mM Tris-HCL pH 6.8, 2% w/v SDS, 10% glycerol, 5% ßME, 0.01% bromophenol blue).
Extracts were sonicated for 10 s on ice to reduce viscosity. Equal volumes of protein extracts were heated at 95ºC for 5 min and separated on a 10% acrylamide gel.
Membranes were blocked in TBST (100 mM NaCl, 10 mM Tris, pH 7.5, and 0.1% Tween 20) containing 5% nonfat milk, and incubated at 4ºC overnight with antibodies against Phospho-p38, Phospho -JNK, or Phospho-ERK 1/2, diluted 1:1000 in TBST containing 5% BSA. After washing, membranes were incubated for 1 h at room temperature with appropriate secondary antibodies (diluted 1:5000 in TBST/5% nonfat milk), washed with TBST, and immunoreactive bands were visualized by chemiluminescence. Blots were stripped for 1 h at room temperature in stripping solution (62.5 mM Tris pH 6.8, 2%SDS, and 0.7% (v/v) ß-mercaptoethanol), followed by extensive washing in TBST. Phospho-p38 and phospho-JNK blots were reassayed for phospho-ERK, while phospho-ERK blots were reincubated with a total ERK 1/2 or ERK 2 antibody (diluted 1:1000) in TBST/5% BSA at 4ºC overnight, incubated with appropriate secondary antibodies, and immunoreactive bands visualized by chemiluminescence.
DBH Immunoblot Analysis: Sympathetic neurons were treated 5-8 days with 50 or 100 ng/ml CNTF, with or without PD98059 as indicated in the figure legends.
PD98059 was added 30 min prior to adding CNTF. PD98059 was added every other day, and media were replaced every 3-4 days. Cells were rinsed with PBS, and protein extracts were collected on ice in ERK lysis buffer. 5-10 µg of protein was diluted 1:2 with sample buffer, heated at 95ºC for 5 min, sized fractionated on 10% SDS-PAGE gels, and transferred to membranes. Membranes were blocked in 5% nonfat dried milk/TBST, incubated overnight at 4ºC with rabbit anti-DBH (diluted 1:1000 in TBST/5% milk), washed, incubated 1 h at room temperature with goat anti-rabbit HRP (diluted 1:10,000 in TBST/5% milk), and immunoreactive bands visualized by chemiluminescence. Band intensity was recorded by a -40ºC CCD camera, or Kodak X-Omat film, and analyzed using LabWorks software (UVP, Upland, CA). To quantify DBH protein levels, the band density obtained for DBH was normalized to the protein in that sample. An arbitrary value of 1 was assigned to the DBH value obtained in untreated control cultures. Total and mean band density gave similar results.
Transient Transfection and Reporter Assays: DNA used for transfection was purified using the Qiagen Maxiprep kit. M17 cells were plated at a density of 2-2. (Fig. 1) .
Similar results were obtained using serum-free OptiMEM, but subsequent experiments were carried out in the presence of serum.
To determine if these cytokines also activated p38 or JNKs in sympathetic neurons, cells were stimulated for 15 minutes with LIF (10 ng/ml) or one hour with anisomycin (10 µg/ml), a cell permeable activator of p38 and JNK, as a positive control.
LIF did not stimulate phosphorylation of either p38 (Fig. 1B) or JNK (Fig. 1C) . The lack of p38 or JNK phosphorylation was not due to a lack of cytokine activity, since all blots were stripped and reblotted with a phospho-ERK antibody, confirming that LIF had induced ERK phosphorylation. A total ERK 2 antibody was used on the same blots to confirm equivalent protein loading and transfer. Total ERK was used to control for protein loading because total p38 levels were very low in these cells (data not shown; (33) .
Immunoblot analysis revealed that LIF and CNTF stimulated phosphorylation of ERK. To determine if phospho-ERK remained in the cytoplasm or translocated to the nucleus, neurons were treated for varying times with CNTF, and total and phospho-ERK were visualized by double label immunofluorescence. CNTF-induced ERK phosphorylation was visible in both the neurites and in the cell soma within 15 minutes.
Although some nuclear phospho-ERK was visible, widespread translocation of phospho-ERK from the cytoplasm to the nucleus was not observed up to two hours after treatment (Fig. 2) .
To test whether ERKs were required for the LIF or CNTF-mediated downregulation of DBH protein, the MEK inhibitor PD98059 was used to prevent phosphorylation and activation of ERK 1&2. 20 µM PD98059 was sufficient to inhibit the phosphorylation of ERK induced by exposure to 100 ng/ml CNTF (Fig 3A) . Neurons were treated for 5-8 days with 100 ng/ml LIF or CNTF, with or without 20 µM PD98059. DBH levels were assessed by immunoblot analysis and normalized to total protein.
Addition of PD98059 elevated basal levels of DBH, and blocked the suppression of DBH by cytokines (Fig 3B, C) . LIF and CNTF decrease DBH mRNA in sympathetic neurons as well (21) , raising the possibility that these cytokines inhibit transcription of the DBH gene. To determine if this occurred, reporter assays were carried out with the DBH promoter in SK-N-BE(2)M17 neuroblastoma cells (M17 cells). These cells express DBH mRNA (34) as well as the receptor subunits required for LIF and CNTF signaling 2 , suggesting that they are a suitable model for these studies. LIF stimulated phosphorylation of ERK 1&2, but caused no detectable phosphorylation of p38 or JNKs in M17 cells (Fig. 4) , indicating that LIF activated the same MAPK pathways in these cells as in sympathetic neurons.
To determine if LIF or CNTF inhibited DBH transcription, M17 cells were treated for two days with cytokines and then transfected with a reporter construct containing the proximal 394 base pairs of the rat DBH promoter driving firefly luciferase (394DBH-Luc) (26) . Treatment of cells with either LIF or CNTF resulted in decreased DBH promoter activity (Fig. 5A) . As a positive control for cytokine treatments and cell viability, cells were transfected with a cytokine-responsive VIP promoter construct (CyRE:VIP-LUC) (35) .
VIP promoter activity was stimulated by the same treatments that inhibited DBH promoter activity (Fig. 5B) , indicating that cytokines did not disrupt cell viability or cause non-specific suppression of transcription. (data not shown) increased basal activation of the DBH promoter in M17 cells (Fig. 7) .
The decrease in transcriptional activity between cells treated with MEK inhibitor alone and MEK inhibitor plus CNTF was similar to the decrease in transcription between untreated and CNTF-treated cells. This suggests that ERK decreases basal expression of DBH mRNA, but is not involved in the suppression of DBH transcription by LIF or CNTF.
Given the difference between the regulation of DBH protein in neurons and the regulation of DBH transcription in M17 cells, endogenous DBH mRNA was measured in sympathetic neurons using real time PCR. CNTF decreased DBH mRNA levels as expected, and this was not altered by chronic MEK 1/2 inhibition with PD98059 (Fig. 8) .
Preventing ERK activation with PD98059 elevated basal DBH mRNA levels, consistent with the increased transcriptional activity observed with MEK inhibitors. These data indicate that ERKs were not required for the cytokine-mediated downregulation of DBH mRNA, but that ERK activity decreased the basal level of DBH gene expression.
In the absence of cytokines, chronic blockade of ERK activation with MEK inhibitors increased DBH transcription and mRNA. This suggests that under basal conditions ERK inhibits DBH transcription. The transcriptional activator Phox2a/Arix, which stimulates DBH transcription, is inhibited by phosphorylation (39) . To test whether ERK 1&2 decreased Phox2a activity under basal conditions, Phox2a/Arix was transfected, along with the 394DBH-Luc reporter, into M17 cells grown with or without PD98059 for 2 days to prevent ERK activation. 394DBH-Luc promoter activity was assayed two days after transfection. Addition of exogenous Phox2a into cells maintained in PD98059 caused a synergistic increase in 394DBH-Luc activity compared to Phox2a or PD98059 alone (Fig. 9) . This suggests that, under basal conditions, ERK activity decreased DBH transcription by stimulating the phosphorylation of Phox2a, rendering it less active.
Discussion:
Cholinergic differentiation factors induce cholinergic and suppress noradrenergic properties in sympathetic neurons, and it is not clear how a single protein simultaneously elicits two such distinct changes in neurotransmitter phenotype. CDFs activate both the Jak/STAT and the Ras/MAP kinase signaling cascades, and one attractive hypothesis is that the STAT pathway induces cholinergic and peptidergic properties, while the Ras/MAP Kinase pathway suppresses noradrenergic function.
Consistent with this idea, STATs are required for activation of the ChAT and VIP promoters (40) (41) (42) , while Ras activation has little affect on induction of either of these genes in some systems (43) . In other cell lines, STAT activity is potentiated by serine/threonine kinases, suggesting there is cross talk between the Ras/MAPK and STAT pathways (19) .
We investigated the downregulation of DBH in sympathetic neurons to determine if activation of a MAP kinase pathway was crucial for suppression of noradrenergic function. The suppression of noradrenergic properties is well-characterized in sympathetic neurons, but the signaling pathways activated by LIF and CNTF have not been thoroughly investigated in these cells. We found that LIF and CNTF activated ERK 1&2 in sympathetic neurons, consistent with the observation that LIF and CNTF activate ERK 1&2 in these cells in the absence of NGF (31) . In contrast, we saw no evidence for cytokine activation of p38 or JNK in sympathetic neurons. Although we carried out time courses for up to one hour, we cannot exclude the possibility that these pathways were activated in sympathetic neurons over a longer time frame. However, it is unlikely that either of these pathways is critical for the regulation of neurotransmitter phenotype since p38 levels are very low in these cells (33) , and JNK activation in these cells is associated with apoptosis rather than differentiation (44) .
Prolonged inhibition of ERK prevented the cytokine-induced downregulation of DBH protein, but had no effect on cytokine suppression of DBH mRNA (Fig. 10) Our data suggest that the decreases in DBH mRNA and transcription are mediated through one or more ERK independent pathways. The SHP-2 phosphatase, which is involved in the activation of ERK 1&2, can also recruit PI3 kinase which stimulates downstream effectors including mTOR (56) . CNTF activation of mTOR, and subsequently p70S6 Kinase, increases transcription from the VIP promoter due to serine phosphorylation of STAT3 (57) . p70S6K can interact with other transcription factors as well (58) , and may be involved in the suppression of DBH transcription. Thus, there are several ERK-independent mechanisms by which LIF and CNTF could decrease DBH gene expression. 
